Table 2.
Diagnostic values of each PSA cutoff for tumor diagnosis
| PSA (ng/mL) cutoff point | Sensitivity | Specificity | PPV | NPV | LHR+ | LHR− | AuROC |
|---|---|---|---|---|---|---|---|
| 4 | 98.0 (97.2–98.8) | 9.3 (7.6–11.0) | 37.2 (34.3–40.0) | 89.3 (87.5–91.1) | 1.08 (1.05–1.11) | 0.22 (0.10–0.45) | 0.536 (0.524–0.549) |
| 10 | 81.5 (79.2–83.8) | 55.5 (52.6–58.4) | 50.1 (47.1–53.1) | 84.6 (82.4–86.7) | 1.83 (1.67–2.01) | 0.33 (0.26–0.41) | 0.685 (0.658–0.711) |
| 20 | 65.8 (63.0–68.6) | 87.5 (85.6–89.5) | 74.3 (71.7–76.8) | 82.4 (80.1–84.6) | 5.27 (4.29–6.48) | 0.39 (0.34–0.45) | 0.767 (0.740–0.793) |
| 50 | 47.8 (44.9–50.8) | 98.2 (97.4–99.0) | 93.6 (92.1–95.0) | 77.5 (75.0–79.9) | 26.54 (15.3–45.9) | 0.53 (0.48–0.58) | 0.730 (0.705–0.755) |
| 100 | 34.4 (31.6–37.2) | 99.7 (99.4–100.0) | 98.6 (97.8–99.2) | 73.5 (70.9–76.1) | 124.12 (30.89–498.66) | 0.66 (0.61–0.71) | 0.671 (0.647–0.694) |
95% Confidence interval in parentheses.
PSA, prostate-specific antigen; PPV, positive predictive value; NPV, negative predictive value; LHR+, positive likelihood ratio; LHR−, negative likelihood ratio; AuROC, area under the receiver operating characteristic curve.